Results 71 to 80 of about 4,657 (257)
Cyclic AMP signalling in pancreatic islets [PDF]
, 2010 Cyclic 3'5'AMP (cAMP) is an important physiological amplifier of glucose-induced insulin secretion by the pancreatic islet β-cell, where it is formed by the activity of adenylyl cyclases, which are stimulated by glucose, through elevation in ...
Furman, Brian +2 more
core +1 more source
HPRT-deficiency dysregulates cAMP-PKA signaling and phosphodiesterase 10A expression: mechanistic insight and potential target for Lesch-Nyhan Disease? [PDF]
PLoS ONE, 2013 Lesch-Nyhan Disease (LND) is the result of mutations in the X-linked gene encoding the purine metabolic enzyme, hypoxanthine guanine phosphoribosyl transferase (HPRT). LND gives rise to severe neurological anomalies including mental retardation, dystonia,
Ghiabe-Henri Guibinga +2 more
doaj +1 more source
Neural substrates and potential treatments for levodopa-induced dyskinesias in Parkinson's disease [PDF]
, 2016 Parkinson’s disease (PD) is primarily a motor disorder that involves the gradual loss of motor function. Symptoms are observed initially in the extremities, such as hands and arms, while advanced stages of the disease can effect blinking, swallowing ...
Eissa, AM +6 more
core +1 more source
NeuroImage, 2016 Phosphodiesterase 10A (PDE10A) is selectively expressed in the striatal regions in the brain and may play a role in modulating dopaminergic and glutamatergic second messenger pathways. PDE10A inhibitors are expected to be useful in treating neuropsychiatric disorders such as schizophrenia and Huntington's disease. In this study, the brain kinetics of [(
Thomas A. Macek +11 more
openaire +3 more sources
Inhibition of phosphodiesterase10A attenuates morphine-induced conditioned place preference [PDF]
, 2014 Background Phosphodiesterase (PDE) 10A is selectively expressed in medium spiny neurons of the striatum. Nucleus accumbens (NAc) is a key region that mediates drug reward and addiction-related behaviors. To investigate the potential role of PDE10A in the
Bo Gao +7 more
core +3 more sources
Pharmaceuticals, 2022 The facilitation of corticostriatal transmission is modulated by the pharmacological inhibition of striatal phosphodiesterase 10A (PDE10A). Since L-DOPA-induced dyskinesia is associated with abnormal corticostriatal transmission, we hypothesized that ...
Rayanne Poletti Guimarães +5 more
doaj +1 more source
Chorea-related mutations in PDE10A result in aberrant compartmentalization and functionality of the enzyme [PDF]
, 2020 A robust body of evidence supports the concept that phosphodiesterase 10A (PDE10A) activity in the basal ganglia orchestrates the control of coordinated movement in human subjects.
Baillie, George S. +7 more
core +1 more source
Positron emission tomography assessments of phosphodiesterase 10A in patients with schizophrenia [PDF]
, 2022 [Background and hypothesis] Phosphodiesterase 10A (PDE10A) is a highly expressed enzyme in the basal ganglia, where cortical glutamatergic and midbrain dopaminergic inputs are integrated.
Higuchi, Makoto +16 more
core +1 more source
Frontiers in Bioengineering and Biotechnology, 2022 Our previous work showed that [18F]P10A-1910 was a potential radioligand for use in imaging phosphodiesterase 10A (PDE10A). Specifically, it had high brain penetration and specific binding that was demonstrated in both rodents and non-human primates ...
Huiyi Wei +16 more
doaj +1 more source
Targets for future clinical trials in Huntington's disease: What's in the pipeline? [PDF]
, 2014 The known genetic cause of Huntington's disease (HD) has fueled considerable progress in understanding its pathobiology and the development of therapeutic approaches aimed at correcting specific changes linked to the causative mutation.
Tabrizi, SJ, Wild, EJ
core +1 more source